Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06420557 · ClinicalTrials.gov registry record · NA

Unconscious Reduction of Fear Through Decoded Neuro-Reinforcement

A NA study of Phobia, sponsored by University of California, Los Angeles.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT06420557: Recruiting NA study of Phobia, sponsored by University of California, Los Angeles.

NCT06420557 is a NA study of Phobia that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06420557, a NA study of Phobia, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This application investigates the efficacy of a novel method of neuro-reinforcement based on decoded fMRI activity to reduce fear responses in individuals with phobias (e.g., spiders, snakes). This method works unconsciously in the brain, without the need for participants to endure repeated conscious exposures to their feared stimuli. Fear-related disorders such as specific phobia, post-traumatic stress disorder (PTSD), and other anxiety disorders present a major challenge, as effective treatment options usually involve repeated exposures to feared stimuli, leading to high levels of distress, fear, and panic that can motivate premature treatment termination. Consequently, there is an unmet need for treatment that minimizes subjective discomfort and attrition in order to maximize efficacy. Recent developments in computational neuroimaging have enabled a method that can deliver unconscious exposure to feared stimuli, resulting in effective fear reduction while bypassing a primary cause of treatment attrition. Because this treatment method happens unconsciously in the brain, changes in behavior outcomes are potentially more likely to generalize to different contexts, thereby overcoming a limitation of traditional treatments.

Primary Outcome

The neural measure of difference in amygdala reactivity (measured by fMRI) to target phobic animals compared to control phobic animals from pre-treatment to post-treatment. Lower numbers (i.e. more negative numbers) indicate greater amygdala decrease and and better outcomes.

Conditions Studied

Interventions

  • BEHAVIORAL Unconscious Neuro-reinforcement

Study Locations (1)

California

  • University of California, Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-09-09
Est. Completion 2026-09-30
Phase NA

What NCT06420557 shows while recruiting

NCT06420557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Phobia appearing as the primary indexed condition, and to 1 intervention - of which Unconscious Neuro-reinforcement is the first listed.

NCT06420557 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06420557 about?

NCT06420557 is a clinical study titled "Unconscious Reduction of Fear Through Decoded Neuro-Reinforcement". This application investigates the efficacy of a novel method of neuro-reinforcement based on decoded fMRI activity to reduce fear responses in individuals with phobias (e.g., spiders, snakes). This method works unconsciously in the brain, without the need for participants to endure repeated consciou...

What is the current status of trial NCT06420557?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-09-09. Estimated completion is 2026-09-30.

What conditions does trial NCT06420557 study?

This clinical trial studies the following conditions: Phobia.

What interventions are being tested in trial NCT06420557?

The interventions under investigation include: Unconscious Neuro-reinforcement (BEHAVIORAL).

Who is sponsoring clinical trial NCT06420557?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06420557 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Phobia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06420557's enrollment target sits among peer trials

60 1165th of 2000 higher than 745 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06420557, the US trial registry maintained by the National Library of Medicine. NCT06420557 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.